Dana-Farber/Brigham and Women's physician wins prestigious recognition from ASH

(Dana-Farber Cancer Institute) Benjamin Ebert, M.D., Ph.D., current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting. Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Abstract Myelodysplastic syndromes (MDS) are a varied set of hematologic neoplasms and a high risk of progression to acute myeloid leukemia (AML). 4-Amino-2-trifluoromethyl-phenyl retinate (ATPR), a novel all-trans retinoic acid (ATRA) derivative, play an important role in various types of cancer cells as a tumor inhibitor. However, little is known concerning its antitumor effect on MDS. The cell viability and the percentage of apoptotic cells were used to measure MTT, Flow Cytometry and Hoechst 33342/PI staining. In addition, real-time quantitative RT-PCR (qRT-PCR) and western blotting were used to analyzed the e...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and related disorders are a heterogeneous class of blood cancers leading to ineffective hematopoiesis in the bone marrow (BM) [1, 2]. Approximately 30% of MDS patients progress to acute leukemia. Median survival ranges from 97 months for low risk categories, down to 11 months for high risk MDS [2]. The incidence of MDS in the general population is ∼4-5 per 100,000 people, but this increases with age [1]. Population based studies in both Australia and the USA indicate a significant underestimation of the true burden of MDS, with freq...
Source: Experimental Hematology - Category: Hematology Authors: Tags: Review Source Type: research
Pediatric Blood&Cancer, EarlyView.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Source Type: research
Mutations affecting the spliceosomal protein U2AF1 are commonly found in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). We have generated mice that carry Cre-dependent knock-in alleles of U2af1(S34F), the murine version of the most common mutant allele of U2AF1 encountered in human cancers. Cre-mediated recombination in murine hematopoietic...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: PNAS Plus Source Type: research
Conclusion(s): Genomewide profiling of cfDNA in apparently healthy individuals enables the detection of incipient hematological malignancies as well as clonal mosaicism with unknown clinical significance. CNA screening of cellular DNA of peripheral blood in elderly has established that clonal mosaicism for these chromosomal anomalies predicts a 5 to 10-fold enhanced risk of a subsequent cancer. We demonstrate that cfDNA screening detects CNAs, which are not only derived from peripheral blood, but even more from other tissues. Since the clinical relevance of clonal mosaics in other tissues remains unknown, long-term follow-...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Oncol Source Type: research
Authors: Sachiyo O, Masahiro T, Tsutomu T, Makoto I, Yutaka H, Nobumasa M, Takamichi K, Nozomi O, Shinpei M, Kazuhiro T, Yusuke K, Masanori O, Yusuke K, Yasuhisa H, Kazuo H, Yasumasa N Abstract Fanconi anemia (FA) is a disorder of chromosomal fragility characterized by progression to aplastic anemia, myelodysplastic syndrome, and leukemia. FA patients are also predisposed to solid cancers. A case of FA in an adult patient who developed tongue and superficial esophageal cancers following hematopoietic stem cell transplantation is reported. This case was considered significant because it is the first reported case of...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Publication date: Available online 10 October 2018Source: Cancer GeneticsAuthor(s): Rashmi Kanagal-Shamanna, Jennelle C. Hodge, Tracy Tucker, Shashi Shetty, Ashwini Yenamandra, Amanda Dixon-McIver, Christine Bryke, Emma Huxley, Patrick A. Lennon, Gordana Raca, Xinjie Xu, Sally Jeffries, Fabiola Quintero-Rivera, Patricia T. Greipp, Marilyn L. Slovak, M. Anwar Iqbal, Min FangAbstractMultiple studies have demonstrated the utility of chromosomal microarray (CMA) testing to identify clinically significant copy number alterations (CNAs) and copy-neutral loss-of-heterozygosity (CN-LOH) in myeloid malignancies. However, guidelines...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Genes, Chromosomes and Cancer,Volume 0, Issue ja, -Not available-.
Source: Genes, Chromosomes and Cancer - Category: Cancer & Oncology Authors: Source Type: research
EAST SETAUKET, NY , Oct. 09, 2018 -- (Healthcare Sales &Marketing Network) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of Lixte’s... Biopharmaceuticals, Oncology, FDA Lixte Biotechnology, protein phosphatases, Myelodysplastic Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Myelodysplastic Syndrome | Women